Diagnosing the decline in pharmaceutical R&D efficiency
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (RD). Yet the number of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining RD efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For over fifty years, the pharmaceutical industry has seen the cost of developing drugs increase exponentially from tens of millions in the 1950s to billions of dollars today, even when the data is adjusted for inflation [1].”
From Drug design on quantum computers (2024) · doi:10.1038/s41567-024-02411-5 · cites this paper as [1]
Citations
Cites
Collective dynamics of ‘small-world’ networks
Watts, D. J., & Strogatz, S. H. (1998) · Nature · doi:10.1038/30918 · Cited by 43,060
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“It is hard to look at the genesis of drugs like crizotini”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“First, estimates of the number of potential drug target”
Background
Research works printed but not linked: 6
- Ruffolo, R. R. Engineering success: Wyeth redefines its research & development organisation. Drug Discovery World website [online] , (2005).
- Young, M. P. Prediction v Attrition. Drug Discovery World website [online] , (2008).
- Healy, D. The Psychopharmacologists: Volume 2 93–118 (Hodder Arnold, London, 1999).
- Healy, D. The Psychopharmacologists: Volume 2 259–264 (Hodder Arnold, London, 1999).
- Mathieu, M. P. (ed.) Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2010/2011 163–261 (Barnett International, Needham, Massachusetts, 2010).
- Munos, B. How to avert biopharma's R&D crisis. In Vivo 29, 2011800050 (2011).
Cited by
Items 901–1,000 of 1,002
Pharmaceutical spending and early-stage innovation in EU countries
Kourouklis, D., & Gandjour, A. (2022) · Industry and Innovation · doi:10.1080/13662716.2021.2021864 · Cited by 12
“…commensurately (Pammolli, Magazzini, and Riccaboni 2011; DiMasi, Grabowski, and Hansen 2016; Ippoliti, Ramello, and Scherer 2021), indicating either R&D inefficiencies (Scannell et al. 2012) or increasing R&D costs per approved molecule (DiMasi, Grabowski, and Hansen 2016; Cleary et al. 2018).”
BackgroundGhufran, M., Rehman, A. U., Ayaz, M., Ul‐Haq, Z., Uddin, R., Azam, S. S., & Wadood, A. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2128878 · Cited by 12
Chemoresistance Mechanisms in Non-Small Cell Lung Cancer—Opportunities for Drug Repurposing
Kaur, R., & Suresh, P. K. (2023) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04595-7 · Cited by 13
Dias, K. S. T., de Paula, C. T., Riquiel, M. M., do Lago, S. T. L., Costa, K. C. M., Vaz, S. M., Machado, R. P., de Lima, L. M. S., & Viegas, C. (2015) · Revista Virtual de Química · doi:10.5935/1984-6835.20150027 · Cited by 21
Evaluating Philosophy as Exploratory Research
Langhe, R. D., & Schliesser, E. S. (2017) · Metaphilosophy · doi:10.1111/meta.12244 · Cited by 12
Hadwen, J., Schock, S., Mears, A. J., Robert Che-An, Y. A. N. G., Charron, P., Zhang, L., Xi, H. S., & MacKenzie, A. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy221 · Cited by 15
Four Stages of Pharmaceutical Product Development
Amarji, B., Abed, S. N., Bairagi, U., Deb, P. K., Al-Attraqchi, O. H. A., Choudhury, A. A., & Tekade, R. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814423-7.00018-6 · Cited by 27
Identification of Novel Analgesics Through a Drug Repurposing Strategy
Gazerani, P. (2019) · Pain Management · doi:10.2217/pmt-2018-0091 · Cited by 12
Towards an African Light Source
Connell, S. H., Mtingwa, S. K., Dobbins, T., Khumbah, N., Masara, B., Mitchell, E. P., Norris, L., Ngabonziza, P., Ntsoane, T. P., & Winick, H. (2019) · Biophysical Reviews · doi:10.1007/s12551-019-00578-3 · Cited by 12
Menagerie: A text-mining tool to support animal-human translation in neurodegeneration research
Zeiss, C. J., Shin, D., Wyk, B. V., Beck, A. P., Zatz, N., Sneiderman, C. A., & Halil Kilicoglu, B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226176 · Cited by 12
Watanabe, U., Sugiura, S., Kakehata, M., Yanagawa, F., Takagi, T., Sumaru, K., Satoh, T., Tamura, M., Hosokawa, Y., Torizuka, K., et al. (2020) · Micromachines · doi:10.3390/mi11070679 · Cited by 12
“In recent years, the cost of drug development has increased exponentially [1], and the success rate of clinical trials has been decreasing every year [2].”
BackgroundDrug delivery—the increasing momentum
Ashford, M. B. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00858-6 · Cited by 13
Grigolo, T. A., Braga, C. B., Ornelas, C., Russowsky, D., Ferreira‐Silva, G. Á., Ionta, M., & Pilli, R. A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105292 · Cited by 12
Improving Translational Paradigms in Drug Discovery and Development
Williams, M. J. (2021) · Current Protocols · doi:10.1002/cpz1.273 · Cited by 12
“…of new drugs approved per billion U.S. dollars spent on R&D has halved roughly every 9 years, declining nearly 80-fold in inflationadjusted terms (Scannell et al., 2012), leading to the conclusion that “powerful sources have outweighed scientific, technical and managerial improvements over the…”
BackgroundInfluentialMaeda, H., Uchida, M., Kusano, M., Tsukamoto, K., & Yamanoi, M. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2641 · Cited by 12
Ruan, L., Su, D., Shao, C., Wang, J., Dong, C., Huang, X., & Ren, J. (2014) · The Analyst · doi:10.1039/c4an01816h · Cited by 12
White spots in pharmaceutical pipelines–EMA identifies potential areas of unmet medical needs
Papaluca, M., Greco, M., Tognana, E., Ehmann, F., & Saint-Raymond, A. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1028918 · Cited by 12
Reformulating the entropic contribution in molecular docking scoring functions
Procacci, P. (2016) · Journal of Computational Chemistry · doi:10.1002/jcc.24397 · Cited by 12
Leveraging Industry‐Academia Collaborations in Adaptive Biomedical Innovation
Stewart, S., Barone, P. W., Bellisario, A., Cooney, C. L., Sharp, P. A., Sinskey, A. J., Natesan, S., & Springs, S. L. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.504 · Cited by 12
“that manufacturers of small molecules are submitting new molecular entities at a decreasing rate.(2) Therefore, new innovations in”
BackgroundEndogenous productivity of demand‐induced R&D: evidence from pharmaceuticals
Myers, K. R., & Pauly, M. V. (2019) · The RAND Journal of Economics · doi:10.1111/1756-2171.12289 · Cited by 13
Health state dependent multiphoton induced autofluorescence in human 3D in vitro lung cancer model
Kilin, V., Mas, C., Constant, S., Wolf, J., & Bonacina, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-16628-3 · Cited by 15
Melge, A. R., Manzoor, K., Nair, S. V., & Mohan, C. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00019-5 · Cited by 15
Mining Natural Compounds to Target WNT Signaling: Land and Sea Tales
Katanaev, V. L., Blagodatski, A. S., Xu, J., Khotimchenko, Y. S., & Koval, A. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_530 · Cited by 15
Mathematical modeling of efficacy and safety for anticancer drugs clinical development
Lavezzi, S. M., Borella, E., Carrara, L., Nicolao, G. D., Magni, P., & Poggesi, I. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1388369 · Cited by 12
“Mathematical models might also be used retrospectively, in order to routinely analyze failures, so as to identify both the specific causes that led to attrition and the stages of development that are more at risk [111].”
MethodSharing R&D Risk in Healthcare via FDA Hedges
Jørring, A., Lo, A. W., Philipson, T., Singh, M., & Thakor, R. T. (2021) · The Review of Corporate Finance Studies · doi:10.1093/rcfs/cfab024 · Cited by 13
Drivers of Orphan Drug Development
Mingorance, A. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00438 · Cited by 12
Bioelectronic Medicine—Ethical ConcernsPreprint
Packer, S., Mercado, N. R., & Haridat, A. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034363 · Cited by 13
Milenković, U., Ilg, M. M., Cellek, S., & Albersen, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1591370 · Cited by 12
Chemoinformatics: From Chemical Art to Chemistry in Silico
Polański, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.20189-1 · Cited by 14
Cancer 3D Models for Metallodrug Preclinical Testing
Engrácia, D. M., Pinto, C. I. G., & Mendes, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511915 · Cited by 11
“The majority of clinically tested drugs fail during clinical trials due to inadequate effectiveness or excessive toxicity, resulting in a significant financial loss [193].”
BackgroundDo R&D tax credits impact pharmaceutical innovation? Evidence from a synthetic control approach
Oliver, E., Kourouklis, D., & Jofre‐Bonet, M. (2024) · Research Policy · doi:10.1016/j.respol.2024.105053 · Cited by 11
Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)
Schuhmacher, A., Gassmann, O., Hinder, M., & Hartl, D. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104128 · Cited by 11
Drug repurposing of fluoroquinolones as anticancer agents in 2023
Kassab, A. E., Gomaa, R. M., & Gedawy, E. M. (2024) · RSC Advances · doi:10.1039/d4ra03571b · Cited by 11
Assessing the Utility of Organoid Intelligence: Scientific and Ethical Perspectives
Nestor, M. W., & Wilson, R. L. (2025) · Organoids · doi:10.3390/organoids4020009 · Cited by 13
“Eroom’s Law, described by Scannell et al. [37], highlights the paradoxical decline in pharmaceutical research and development (R&D) productivity despite advances in scientific knowledge and technology.”
Network‐based precision medicine and systems pharmacology
Pandey, A. K., Ghiassian, S. D., & Loscalzo, J. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70184 · Cited by 14
“When normalised to inflation-adjusted yearly research expenditures, drug development efficiency has declined nearly 80-fold from 1950 to 2010 (Scannell et al., 2012).”
Ellison, S. T., Hayman, I., Derr, K., Derr, P., Frebert, S., Itkin, Z., Shen, M., Jones, A., Olson, W., Corey, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64245-w · Cited by 12
Vost, L., Ziv, Y., & Deane, C. M. (2025) · Chemical Science · doi:10.1039/d5sc05748e · Cited by 12
A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases
Zang, Y., Shi, J., Zhao, G., Tang, B., Liu, M., Yao, B., Wang, G., Pan, H., Yang, S., Deng, R., et al. (2026) · Nature · doi:10.1038/s41586-026-10633-1 · Cited by 14
“This high failure rate—often due to unexpected toxicity or insufficient efficacy at tolerable doses—suggests fundamental flaws in current drug development paradigms 18,19 .”
Differentiation of small alkane and alkyl halide constitutional isomers via encapsulation
Sullivan, M. R., & Gibb, B. C. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob02357a · Cited by 11
Ward, D. J., Hammond, E. R., Linden-Phillips, L., & Stevens, A. J. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009333 · Cited by 11
Burt, T., MacLeod, D. B., Lee, K. J., Santoro, A., DeMasi, D. K., Hawk, T. C., Feinglos, M. N., Rowland, M., & Noveck, R. J. (2017) · Clinical and Translational Science · doi:10.1111/cts.12477 · Cited by 11
Rakers, C., Najnin, R. A., Polash, A. H., Takeda, S., & Brown, J. B. (2017) · ChemMedChem · doi:10.1002/cmdc.201700677 · Cited by 12
Can Financial Economics Cure Cancer?
Lo, A. W. (2021) · Atlantic Economic Journal · doi:10.1007/s11293-021-09704-7 · Cited by 11
A comprehensive review on the application of artificial intelligence in drug discovery.
Sahoo, A., & Dar, G. M. (2021) · The Applied Biology & Chemistry Journal · doi:10.52679/tabcj.2021.0007 · Cited by 15
Zhang, B., Zhao, J., Guo, P., Wang, Z., Xu, L., Liu, A., & Du, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111916 · Cited by 11
Peters, M. S., Park, C. H. J., Turner, A., Guerin, A. A., & Kim, J. H. (2023) · Addiction Neuroscience · doi:10.1016/j.addicn.2023.100064 · Cited by 11
Computational Advancements in Cancer Combination Therapy Prediction
Flanary, V. L., Fisher, J. L., Wilk, E. J., Howton, T. C., & Lasseigne, B. N. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00261 · Cited by 12
Beyond the hype and toward application: liver complex in vitro models in preclinical drug safety
Jadalannagari, S., & Ewart, L. C. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2328794 · Cited by 14
“Thus, the R&D productivity crisis described as Eroom’s law [4] remains as relevant today as it was a decade ago.”
Drug Targets, Target Identification, Validation, and Screening
den Broeck, W. M. M. V. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00003-1 · Cited by 12
Oh, J., Yi, S., Gu, N., Shin, D., Yu, K., Yoon, S. H., Cho, J., & Jang, I. (2018) · Genomics & Informatics · doi:10.5808/gi.2018.16.3.52 · Cited by 11
“Dramatic improvements were made in pre-clinical research areas, but the successful clinical development rate of new drug candidates has not changed in recent years [1].”
BackgroundDeveloping RNA Aptamers for Potential Treatment of Neurological Diseases
Huang, Z., & Niu, L. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0364 · Cited by 11
Partnerships for better neglected disease drug discovery and development: how have we fared?
Sunyoto, T. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1736550 · Cited by 11
Drug Repurposing in Neurological Diseases: Opportunities and Challenges
Mao, X. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.93093 · Cited by 12
Gross, S., & Sohl, C. D. (2021) · Biochemistry and Molecular Biology Education · doi:10.1002/bmb.21491 · Cited by 13
Lim, G., Lim, C. J., Lee, J. H., Lee, B. H., Ryu, J. Y., & Oh, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-96612-0 · Cited by 11
“2 human calcium ion channel binding assay for voltage-dependent L-type calcium channel subunit α-1C (CACNA1C), NET human norepinephrine transporter binding assay for sodiumdependent noradrenaline transporter (SLC6A2), SET human serotonin transporter binding assay for sodiumdependent serotonin transporter (SLC6A4), 5-H…”
BackgroundMethodInfluentialDelegated Concept Testing in New Product Development
Schlapp, J., & Schumacher, G. (2022) · Operations Research · doi:10.1287/opre.2022.2318 · Cited by 13
Cancer medicines: a private vice for public benefit?
Sullivan, R. J. (2024) · ecancermedicalscience · doi:10.3332/ecancer.2024.ed131 · Cited by 11
Okurowska, K., Monk, P. N., & Karunakaran, E. (2024) · Microbiology · doi:10.1099/mic.0.001459 · Cited by 11
Constant, S., Huang, S., Wiszniewski, L., & Mas, C. (2013) · InTech eBooks · doi:10.5772/53391 · Cited by 15
“Indeed, the number of drugs approved by the US Food and Drug Administration (FDA) has roughly fallen to 50% over the last ten years [1].”
BackgroundIdentifying problematic drugs based on the characteristics of their targets
Lopes, T. J. S., Shoemaker, J. E., Matsuoka, Y., Kawaoka, Y., & Kitano, H. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00186 · Cited by 13
“With the costs of compound design dramatically increasing and most of these funds being spent on drugs that never make it to market (Munos, 2009; Scannell et al., 2012), there is a clear need for new technologies to develop more specific, less toxic compounds.”
BackgroundIntraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats
Burt, T., Rouse, D. C., Lee, K., Wu, H., Layton, A. T., Hawk, T. C., Weitzel, D. H., Chin, B. B., Cohen‐Wolkowiez, M., Chow, S., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.160986 · Cited by 11
Data Mining in Drug Discovery and Design
Agatonović-Kuštrin, S., & Morton, D. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801559-9.00009-0 · Cited by 11
Organizational effectiveness: a key to R&D productivity
Tollman, P., Panier, V., Dosik, D., Biondi, P., & Cuss, F. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.91 · Cited by 11
Safavi, M., Sabourian, R., & Abdollahi, M. R. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1217196 · Cited by 12
Hadengue, M., de Marcellis-Warin, N., & Warin, T. (2018) · Management international · doi:10.7202/1043076ar · Cited by 11
Learning from Deep Representations of Multiple Networks for Predicting Drug–Target Interactions
Hu, P., Huang, Y., You, Z., Li, S., Chan, K. C. C., Leung, H., & Hu, L. (2019) · Lecture notes in computer science · doi:10.1007/978-3-030-26969-2_14 · Cited by 11
Drug Discovery and Development: The Role of Artificial Intelligence in Drug Repurposing
Aljofan, M., & Gaipov, A. (2024) · Future Medicinal Chemistry · doi:10.4155/fmc-2024-0048 · Cited by 11
DrugGym: A testbed for the economics of autonomous drug discoveryPreprint
Retchin, M. R., Wang, Y., Takaba, K., & Chodera, J. D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.28.596296 · Cited by 11
“Pharma industry econometrics has been extensively scrutinized, finding steep declines in R&D efficiency [6, 7].”
BackgroundPanting, R. G., Kotecha, R. S., & Cheung, L. C. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104212 · Cited by 10
Jiang, M.-Z., Li, C., Mao, C.-M., Yu, H., Zhou, Y.-C., Pu, S.-Q., Li, R.-Z., Liao, Y., Zhang, D.-Y., Yang, P., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-76465-z · Cited by 13
Xiao, M., Zheng, Q., Popa, P., Mi, X., Hu, J., Zou, F., & Zou, B. (2025) · Scientific Reports · doi:10.1038/s41598-024-84711-7 · Cited by 10
Advanced Artificial Intelligence Technologies Transforming Contemporary Pharmaceutical Research
Kumar, P., Chaudhary, B., Arya, P., Chauhan, R., Devi, S., Parejiya, P. B., & Gupta, M. M. (2025) · Bioengineering · doi:10.3390/bioengineering12040363 · Cited by 14
“This conservative field has placed a premium on developing small size pharmaceuticals that are stable, effective in achieving therapeutic goals, and tolerable for a wide range of users [2,3].”
Development and challenges of mass spectrometry database for traditional Chinese medicine: A review
Wang, Y., Yang, Z., Wu, J., Ma, X., Zhou, L., Li, X., Ma, B., Qiu, Z., & Kang, L. (2025) · Science of Traditional Chinese Medicine · doi:10.1097/st9.0000000000000082 · Cited by 10
The R&D productivity challenge: transforming the pharmaceutical ecosystem
Schuhmacher, A., Gassmann, O., Kwisda, S., Kremer, M., Hinder, M., & Hartl, D. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104494 · Cited by 10
Zhou, X., & Tao, W. (2026) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2026.1755843 · Cited by 11
“…including hit identification, lead optimization, and comprehensive Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADME/Tox) profiling, were labor-intensive and relied predominantly on high-throughput screening (HTS) (Scannell et al., 2012; Hughes et al., 2011; Alqahtani, 2017).”
Sources for Leads: Natural Products and Libraries
van Herwerden, E. F., & Süßmuth, R. D. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_19 · Cited by 10
Academic–Pharma Drug Discovery Alliances: Seeking Ways to Eliminate the Valley of Death
Hammonds, T. R. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.111 · Cited by 10
Nakayama, N., Bando, Y., Fukuda, T., Kawamura, T., Nakamura, H., Marko‐Varga, G., & Nishimura, T. (2015) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2015.11.008 · Cited by 10
Laloo, D., Kalita, J. M., & Prasad, S. K. (2021) · Springer eBooks · doi:10.1007/978-981-15-8127-4_19 · Cited by 10
Riccio, F., Micarelli, E., Secci, R., Giuliani, G., Vumbaca, S., Massacci, G., Castagnoli, L., Fuoco, C., & Cesareni, G. (2022) · Cell Death Discovery · doi:10.1038/s41420-021-00811-7 · Cited by 10
“INTRODUCTION Pharmaceutical companies experience considerable hurdles in the development and marketing of new drugs [1].”
BackgroundSupporting Innovation in Early-Stage Pharmaceutical Development Decisions
Methling, F., Borden, S. A., Veeraraghavan, D., Sommer, I., Siebert, J. U., von Nitzsch, R., & Seidler, M. (2022) · Decision Analysis · doi:10.1287/deca.2022.0452 · Cited by 10
Kalibrierung der Wissenschaft: Auswirkungen der Digitalisierung auf die wissenschaftliche Erkenntnis
Mößner, N., Erlach, K., & Hannover, T. I. (2022) · Science studies · doi:10.1515/9783839462102 · Cited by 10
The Origin of First‐in‐Class Drugs: Innovation Versus Clinical Benefit
Osipenko, L., Potey, P. M., Perez-Villa, B., Angelov, F., Parvanova, I., Ul‐Hasan, S., & Mossialos, E. A. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3110 · Cited by 11
Drug Repurposing in Crohn’s Disease Using Danish Real-World Data
Shakibfar, S., Allin, K. H., Jess, T., Barbieri, M. A., Battini, V., Simoncic, E., Kirchgesner, J., Ulven, T., & Sessa, M. (2024) · Pragmatic and Observational Research · doi:10.2147/por.s444569 · Cited by 12
A data management system for precision medicine
Jacobs, J. J. L., Beekers, I., Verkouter, I., Richards, L. B., Vegelien, A., Bloemsma, L. D., Bongaerts, V. A. M. C., Cloos, J. J., Erkens, F., Gradowska, P. L., et al. (2025) · PLOS Digital Health · doi:10.1371/journal.pdig.0000464 · Cited by 10
Maghsoudi, M., Noorbakhsh, A., Khanizadeh, S., Shokouhyar, S., & Shokoohyar, S. (2025) · Annals of Operations Research · doi:10.1007/s10479-024-06433-3 · Cited by 11
“This technology topic is probably at the saturation phase due to its long utilization and very much adopted by many industries, such as chemical, and pharmaceutical industries for technologies in waste treatment and catalysis respectively (Han et al., 2022; Scannell et al., 2012).”
Wang, L., Cui, Q., Hou, Y., Bai, F., Sun, J., Cao, X., Liu, P., Jiang, M., & Bai, G. (2013) · Journal of Chromatography A · doi:10.1016/j.chroma.2013.10.035 · Cited by 10
McNamee, L. M., & Ledley, F. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082195 · Cited by 10
“the biotechnology industry has largely failed to produce either a robust pipeline of new biopharmaceutical products[1,2] or sustained economic returns.”
BackgroundThe Ethical Implications for Humans in Light of the Poor Predictive Value of Animal Models
Greek, R. (2014) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2014.516129 · Cited by 10
Medicine adaptive pathways to patients (MAPPs): using regulatory innovation to defeat Eroom's law.
Schulthess, D. G., Chlebus, M., Bergstrӧm, R., & Baelen, K. V. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.05.07 · Cited by 10
“around 80-fold in inflation-adjusted terms” (2).”
Connection Map for Compounds (CMC): A Server for Combinatorial Drug Toxicity and Efficacy Analysis
Liu, L., Tsompana, M., Wang, Y., Wu, D., Zhu, L., & Zhu, R. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00397 · Cited by 10
Predicting Target and Chemical Druggability
Oprea, T. I., & Hasselgren, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12342-x · Cited by 12
Critical perspectives on international pharmaceutical innovation: Malthus, Foucault and resistance
Callaghan, C. W. (2018) · Critical Perspectives on International Business · doi:10.1108/cpoib-11-2017-0078 · Cited by 10
Scott, T. J., & Vonortas, N. S. (2019) · The Journal of Technology Transfer · doi:10.1007/s10961-019-09743-y · Cited by 9
“6 See, for example, Woodcock and Woosley (2008) and Scannell et al. (2012).”
BackgroundInfluentialTrends of pharmaceutical corporations’ external innovation strategies: An inverse sigmoid curve
Huang, J. (2021) · Technology in Society · doi:10.1016/j.techsoc.2021.101785 · Cited by 10
Chen, Q., & Krishnan, V. V. (2021) · Scientific Reports · doi:10.1038/s41598-021-00869-4 · Cited by 10
“The Eroom’s Law (the infamous Moore’s law backward) in drug discovery states that the cost for discovering a new drug doubles every nine years 22 .”
BackgroundImmunoinformatics: Pushing the boundaries of immunology research and medicine
Chatanaka, M. K., Ulndreaj, A., Sohaei, D., & Prassas, I. (2021) · ImmunoInformatics · doi:10.1016/j.immuno.2021.100007 · Cited by 10
Haerkens, F., Kikken, C., Kirkels, L. A. M. H., van Amstel, M., Wouters, W., van Doornmalen, E. J. P., Francke, C., & Hughes, S. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10108 · Cited by 10
“Eroom's Law suggests the cost of developing a new drug doubles every 9 years [44, 45].”
BackgroundKou, G., Jahanbakhsh, M., Molaee, M., Abbasi, N., & Shahgholi, M. (2022) · Engineering Analysis with Boundary Elements · doi:10.1016/j.enganabound.2022.08.024 · Cited by 10
Partnership Models for R &D in the Pharmaceutical Industry
Iazzolino, G., & Bozzo, R. (2022) · SpringerBriefs in economics · doi:10.1007/978-3-031-11814-2_3 · Cited by 10
Metadata
- Authors
- Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B.
- Corresponding author
- Scannell, Jack W.
- ORCID
- Scannell, Jack W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-03
- Volume
- 11
- Issue
- 3
- Pages
- 191-200
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2028279608
- Cited by
- 1,981
- References
- 85
- Citations by year
- 2026: 135 · 2025: 123 · 2024: 144 · 2023: 126 · 2022: 141 · 2021: 173 · 2020: 178 · 2019: 144 · 2018: 138 · 2017: 133 · 2016: 155 · 2015: 136 · 2014: 108 · 2013: 103 · 2012: 41
- FWCI
- 47.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- new drug approvals, drug approval rates, drug development costs, regulatory policy, drug regulation, basic research
- MeSH terms
- Animals, Drug Industry, Pharmaceutical Preparations, Humans, Research, Drug Delivery Systems, Efficiency, Organizational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.